Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT‐CVD) study

Verma, Shiv; Goodman, Shaun G.; Tan, Mary; Daneault, Benoit; Lubelsky, Bruce J; Mansour, Samer; Lam, Andy; Laflamme, David; Tymchak, Wayne; Welsh, Robert C.; Rose, R.; Chetty, Rajendra M; Constance, Christian; Cieza, Tomas; Potter, Brian J.; Hartleib, Michael; Khan, Razi; Choi, Richard; Keeble, William; Déry, Jean‐Pierre; Shukla, Dinkar; Chua, Grace L; Bainey, Kevin R.

doi:10.1111/ijcp.14597

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, the 2017 ESC guidelines’ recommendations regarding the prolongation of antiplatelet therapy were not followed in 27% of patients with IHD. Similar numbers have been reported by other authors [ 26 ]. Antiplatelet therapy represents the cornerstone to reduce the risk of new ischemic events in secondary prevention patients [ 9 , 21 , 22 , 24 ].…”

Section: Discussionsupporting

confidence: 93%

Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice: The APALUSA Study

Barrios

Escobar

Suárez

et al. 2022

JCM

View full text Add to dashboard Cite

This study was aimed to ascertain the clinical profile and management of patients with ischemic heart disease (IHD) and/or peripheral artery disease (PAD). In this observational and cross-sectional study developed in 80 hospitals throughout Spain, consecutive adults with stable IHD and/or PAD were included. A total of 1089 patients were analyzed, of whom 65.3% had only IHD, 17.8% PAD and 16.9% both. A total of 80.6% were taking only one antiplatelet agent, and 18.2% were on dual antiplatelet therapy (mainly aspirin/clopidogrel). Almost all patients were taking ≥1 lipid lowering drug, mainly moderate-to-high intensity statins. IHD patients took ezetimibe more commonly than PAD (43.9% vs. 12.9%; p < 0.001). There were more patients with IHD that achieved blood pressure targets compared to PAD (<140/90 mmHg: 67.9% vs. 43.0%; p < 0.001; <130/80 mmHg: 34.1% vs. 15.7%; p < 0.001), LDL-cholesterol (<70 mg/dL: 53.1% vs. 41.5%; p = 0.033; <55 mg/dL: 26.5% vs. 16.0%; p = 0.025), and diabetes (HbA1c < 7%, with SGLT2i/GLP1-RA: 21.7% vs. 8.8%; p = 0.032). Modifications of antihypertensive agents and lipid-lowering therapy were performed in 69.0% and 82.3% of patients, respectively, without significant differences between groups. The use of SGLT2i/GLP1-RA was low. In conclusion, cardiovascular risk factors control remains poor among patients with IHD, PAD, or both. A higher use of combined therapy is warranted.

show abstract

Section: Discussionsupporting

confidence: 93%